Toll Free: 1-888-928-9744
Published: Apr, 2017 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Celiac Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Celiac Disease - Overview 6 Celiac Disease - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 11 Products under Development by Companies 12 Products under Development by Universities/Institutes 14 Celiac Disease - Therapeutics Assessment 15 Assessment by Target 15 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Celiac Disease - Companies Involved in Therapeutics Development 23 Amgen Inc 23 Amyra Biotech AG 23 Calypso Biotech SA 24 Circle33 LLC 24 enGene Inc 25 F. Hoffmann-La Roche Ltd 25 Glenmark Pharmaceuticals Ltd 26 ImmusanT Inc 26 Innovate Biopharmaceuticals Inc 27 Intrexon Corp 27 Sanofi 28 Takeda Pharmaceutical Company Ltd 28 Zedira GmbH 29 Celiac Disease - Drug Profiles 30 AMG-714 - Drug Profile 30 AVX-176 - Drug Profile 32 Biologic for Celiac Disease - Drug Profile 33 BNZ-2 - Drug Profile 34 CALY-002 - Drug Profile 35 ERW-1041E - Drug Profile 36 GBR-830 - Drug Profile 37 Kuma-010 - Drug Profile 38 larazotide acetate - Drug Profile 39 latiglutenase - Drug Profile 42 Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology - Drug Profile 45 Nexvax-2 - Drug Profile 46 Nexvax-3 - Drug Profile 49 Oligonucleotides for Celiac Disease - Drug Profile 50 Protein for Celiac Disease - Drug Profile 51 Recombinant Enzymes to Inhibit Gluten for Celiac Disease - Drug Profile 52 Recombinant Protein for Celiac Disease - Drug Profile 53 RG-7625 - Drug Profile 54 Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 55 Vaccine for Celiac Disease - Drug Profile 56 Vaccine for Celiac Disease - Drug Profile 58 vedolizumab - Drug Profile 59 ZED-1227 - Drug Profile 66 ZED-754 - Drug Profile 67 Celiac Disease - Dormant Projects 68 Celiac Disease - Product Development Milestones 69 Featured News & Press Releases 69 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80
List of Tables
Number of Products under Development for Celiac Disease, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Celiac Disease - Pipeline by Amgen Inc, H1 2017 Celiac Disease - Pipeline by Amyra Biotech AG, H1 2017 Celiac Disease - Pipeline by Calypso Biotech SA, H1 2017 Celiac Disease - Pipeline by Circle33 LLC, H1 2017 Celiac Disease - Pipeline by enGene Inc, H1 2017 Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017 Celiac Disease - Pipeline by ImmusanT Inc, H1 2017 Celiac Disease - Pipeline by Innovate Biopharmaceuticals Inc, H1 2017 Celiac Disease - Pipeline by Intrexon Corp, H1 2017 Celiac Disease - Pipeline by Sanofi, H1 2017 Celiac Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Celiac Disease - Pipeline by Zedira GmbH, H1 2017 Celiac Disease - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.